⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
COGT News
Cogent Biosciences, Inc. Common Stock
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
globenewswire.com
COGT
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
COGT
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
globenewswire.com
COGT
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
globenewswire.com
COGT
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
globenewswire.com
COGT
Internet of Behaviors Market Surges to USD 14.3 Billion by 2033, Propelled by 26.5% CAGR - Verified Market Reports®
prnewswire.com
AVR
TRC
GNAV
VTKA
TRIF
NUAN
QBIT
COGT
CAPL
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
globenewswire.com
COGT
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
globenewswire.com
COGT
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
globenewswire.com
COGT
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
globenewswire.com
COGT